# A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

Source: https://onco.cc/trials/nct07644559/  
OnCo record `nct07644559` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of VS-7375, Cetuximab in pancreatic ductal adenocarcinoma, run by Verastem, Inc., now recruiting.

## Summary

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer is a phase 2 interventional study registered as NCT07644559 by Verastem, Inc., with 180 participants planned, started 2026-06-16 and due to reach its primary completion in 2027-06. Interventions recorded: VS-7375, cetuximab. Conditions listed: Pancreatic Ductal Adenocarcinoma (PDAC), G12D Mutated KRAS. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07644559
- Phase: 2
- Setting: A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and With Cetuximab, in Patients With Metastatic KRAS G12D-Mutated Pancreatic Cancer (TARGET-D 201)
- Sponsor: Verastem, Inc.
- Enrolled: 180

## Sources

- ClinicalTrials.gov NCT07644559: https://clinicaltrials.gov/study/NCT07644559

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- drugs: [Cetuximab](https://onco.cc/drugs/cetuximab/), [VS-7375](https://onco.cc/drugs/vs-7375/)
- companies: [Verastem Oncology](https://onco.cc/companies/verastem/)

---
JSON: https://onco.cc/api/v1/entities/nct07644559.json